These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22682027)

  • 61. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.
    Manier S; Barthelemy M; Fouquet G; Prod'homme C; Le Ray E; Samarcq P; Noel MP; Terriou L; Facon T; Cossment C; Boulanger F; Leleu X
    Leukemia; 2012 Dec; 26(12):2552-4. PubMed ID: 22627696
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
    Tanaka K; Toyota S; Akiyama M; Wakimoto N; Nakamura Y; Najima Y; Doki N; Kakihana K; Igarashi A; Kobayashi T; Ohashi K; Kudo D; Shinagawa A; Takano H; Fujio T; Okoshi Y; Hori M; Kumagai T; Saito T; Mukae J; Yamamoto K; Tsutsumi I; Komeno T; Yoshida C; Yamamoto M; Kojima H;
    Acta Haematol; 2019; 141(2):111-118. PubMed ID: 30726834
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
    Takashima S; Miyamoto T; Kadowaki M; Ito Y; Aoki T; Takase K; Shima T; Yoshimoto G; Kato K; Muta T; Shiratsuchi M; Takenaka K; Iwasaki H; Teshima T; Kamimura T; Akashi K
    Int J Hematol; 2014 Aug; 100(2):159-64. PubMed ID: 24928523
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
    Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
    J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial.
    Roussel M; Moreau P; Hebraud B; Laribi K; Jaccard A; Dib M; Slama B; Dorvaux V; Royer B; Frenzel L; Zweegman S; Klein SK; Broijl A; Jie KS; Wang J; Vanquickelberghe V; de Boer C; Kampfenkel T; Gries KS; Fastenau J; Sonneveld P
    Lancet Haematol; 2020 Dec; 7(12):e874-e883. PubMed ID: 33242444
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
    Benson DM; Panzner K; Hamadani M; Hofmeister CC; Bakan CE; Smith MK; Elder P; Krugh D; O'Donnell L; Devine SM
    Leuk Lymphoma; 2010 Feb; 51(2):243-51. PubMed ID: 20038230
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
    Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
    Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL; Avet-Loiseau H; Attal M; Charbonnel C; Garban F; Hulin C; Michallet M; Facon T; Garderet L; Marit G; Ketterer N; Lamy T; Voillat L; Guilhot F; Doyen C; Mathiot C; Moreau P
    J Clin Oncol; 2009 Dec; 27(34):5720-6. PubMed ID: 19826130
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Toxicity of autologous hematopoietic cell transplantation in patients with multiple myeloma - comparison between two different induction regimens.
    Ram R; Magen-Nativ H; Vidal L; Herscovici C; Peck A; Raanani P; Shpilberg O; Yeshurun M
    Clin Transplant; 2012; 26(5):E549-54. PubMed ID: 23061765
    [TBL] [Abstract][Full Text] [Related]  

  • 70. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.
    Morgan GJ; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Johnson PR; Rudin C; Drayson MT; Owen RG; Ross FM; Russell NH; Jackson GH; Child JA;
    Haematologica; 2012 Mar; 97(3):442-50. PubMed ID: 22058209
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
    Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P
    Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440
    [No Abstract]   [Full Text] [Related]  

  • 74. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM.
    Tang HKK; Fung CY; Hwang YY; Lee H; Lau G; Yip SF; Kho B; Lau CK; Leung KH; Au E; Tse E; Sim J; Kwong YL; Chim CS
    Bone Marrow Transplant; 2024 May; 59(5):660-669. PubMed ID: 38383715
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
    Libourel EJ; Sonneveld P; van der Holt B; de Maat MP; Leebeek FW
    Blood; 2010 Jul; 116(1):22-6. PubMed ID: 20339094
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.
    Takamatsu H; Munemoto S; Murata R; Terasaki Y; Nakajima K; Nakao S
    Anticancer Res; 2013 Dec; 33(12):5681-5. PubMed ID: 24324117
    [TBL] [Abstract][Full Text] [Related]  

  • 77. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.
    Pineda-Roman M; Zangari M; van Rhee F; Anaissie E; Szymonifka J; Hoering A; Petty N; Crowley J; Shaughnessy J; Epstein J; Barlogie B
    Leukemia; 2008 Jul; 22(7):1419-27. PubMed ID: 18432260
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Total therapy with tandem transplants for newly diagnosed multiple myeloma.
    Barlogie B; Jagannath S; Desikan KR; Mattox S; Vesole D; Siegel D; Tricot G; Munshi N; Fassas A; Singhal S; Mehta J; Anaissie E; Dhodapkar D; Naucke S; Cromer J; Sawyer J; Epstein J; Spoon D; Ayers D; Cheson B; Crowley J
    Blood; 1999 Jan; 93(1):55-65. PubMed ID: 9864146
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.